Form 4: Imunon Inc. Officer Receives Stock Grant

Imunon, Inc. reports a stock grant to Chief Medical Officer Douglas Faller, issued in lieu of a cash bonus.

Summary

• Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received a grant of 21,896 shares of common stock on June 25, 2026.
• This stock grant was issued in lieu of 50% of his 2025 annual cash bonus.
• The shares were valued at $1.72 per share at the time of the transaction.
• Following this transaction, Mr. Faller beneficially owns 21,896 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports a standard executive compensation transaction rather than significant financial or strategic news.

Positives

• Company is compensating its Chief Medical Officer with equity, aligning incentives.
• The transaction indicates a commitment to retaining key executive talent.

Negatives

• The company is paying a portion of executive compensation in stock rather than cash, which could suggest cash flow constraints.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that executive compensation structures, particularly the use of stock grants in lieu of cash, are common in the biotechnology and pharmaceutical sectors as companies aim to conserve cash while incentivizing leadership. This practice is often seen during development stages or periods of significant investment.

Related Party Transactions

• Grant of 21,896 shares of common stock to Chief Medical Officer Douglas Vincent Faller in lieu of 50% of his 2025 annual cash bonus.

Stakeholder Impact

• Shareholders: Dilution is minimal given the relatively small number of shares granted. The alignment of executive incentives with shareholder interests is a positive aspect.
• Employees: May observe executive compensation practices, potentially influencing morale or perceptions of company financial health.
• Management: Direct impact on the Chief Medical Officer's compensation and beneficial ownership.

Key Dates

Keywords

Imunon Inc., IMNN, Form 4, Stock Grant, Executive Compensation, Chief Medical Officer, Beneficial Ownership, Securities Exchange Act